Paras Healthcare Limited · NSE:PARASHLTH
Paras Healthcare — Q2 & H1 FY27 Earnings Presentation
33 slides from Paras Healthcare's earnings presentation, Nov 6, 2026
Slide 1: Exchange filing cover letter for investor presentation
Date: November 06, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400001 Bandra (E), Mumbai – 400051 BSE Scrip Code: 545005 NSE Scrip Symbol: PARASHLTH Subject: Investor Present
Slide 2: Paras Healthcare Limited Investor Presentation Q2 & H1 FY27
Paras Healthcare Limited Two Decades of Excellence 8 Hospitals (2 upcoming) across 6 States and 1 Union Territory Targeting 3,011 Beds by 2028 Investor Presentation Investor Presentation Q2 & H1 FY27 Q2 & H1 FY27 Our Hospitals : Gurugram, Patna, Darbhanga, Panchkula, Ranchi, Udaipur, Srinagar and Ka
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Paras Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Q2 & H1 FY27 Operational & Financial Highlights
Q2 & H1FY27 Operational & Financial Highlights
Slide 5: Q2 FY27 vs Q2 FY26: Momentum Across Revenue and Profits
Q2 FY27 Vs Q2 FY 26: Momentum Across Revenue and Profits INR 510.9 Crs Revenue +22.8% vs INR 416.1 Crs YoY Growth INR 120.2 Crs Op. EBITDA (Excl other income) +47.0% 23.5% | 19.6% Op. EBITDA Margins vs INR 81.7 Crs YoY Growth growth of 390 bps INR 126.6 Crs Reported EBITDA +42.5% 24.5% | 21.0% Repor
Slide 6: H1 FY27 vs H1 FY26: Growth Compounding into Profitability
H1 FY27 vs H1 FY26 : Growth Compounding into Profitability INR 981.2 Crs Revenue +25.1% vs INR 784.5 Crs YoY Growth INR 225.2 Crs Op. EBITDA (Excl other income) +58.4% 23.0% | 18.1 % Op. EBITDA Margins vs INR 142.2 Crs YoY Growth growth of 480 bps INR 240.1 Crs Reported EBITDA +54.7% 24.1% | 19.5 %
Slide 7: Operating Leverage in Action
Operating Leverage in Action Revenue from Operations (Rs. in Crs) Operating EBITDA & Margin % 981.2 19.6% 23.5% 18.1% 23.0% 784.5 225.2 510.9 142.2 416.1 120.2 81.7 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 22.8% 25.1% 47.0% 58.4% YoY Revenue Growth YoY Revenue Growth YoY EBITDA Growth
Slide 8: Our Hospital Cohorts: FY26
Our Hospital Cohorts : FY26 ~ Mature (>7 years) – 1,076 Beds Emerging (4–7 years) – 500 Beds New (<4 years) – 635 Beds Gurugram Patna Ranchi Udaipur Srinagar Kanpur Darbhanga Panchkula FY26 Revenue ₹1,179 Cr FY26 Revenue ₹283 Cr FY26 Revenue ₹144 Cr Op. EBITDA Op. EBITDA Op. EBITDA ~26% ~15% NM Marg
Slide 9: Q2 FY27: Newer hospitals ramp up continues
OUR HOSPITAL COHORTS Q2 FY27: Newer hospitals ramp up continues Mature Hospitals (> 7 years) Emerging Hospitals (4 to 7 years) New Hospitals (< 4 years) Revenue from Operations (Rs. in Crs) 76.2% 78.1% 53.4% 70.3% 34.4% 78.1% 8.5% 27.2% 138.8% 91.7 84.4 308.7 334.8 72.1 35.3 Q2 FY26 Q2 FY27 Q2 FY26
Slide 10: H1 FY27: Newer hospitals moving to Emerging
OUR HOSPITAL COHORTS H1 FY27: Newer hospitals moving to “Emerging” Mature Hospitals (> 7 years) Emerging Hospitals (4 to 7 years) New Hospitals (< 4 years) Revenue from Operations (Rs. in Crs) 74.0% 76.5% 49.1% 68.6% 27.8% 68.4% 9.1% 43.2% 147.1% 597.2 651.5 183.4 146.3 128.1 59.2 H1 FY26 H1 FY27 H1
Slide 11: Key Financial Ratios
Key Financial Ratios Reported EBITDA Margin Operating EBITDA Margin2 PAT Margin Capital Employed 24.1% 23.0% 9.0% 1,984.6 Cr +465 bps vs H1 FY26 +480 bps vs H1 FY26 +760 bps vs H1 FY26 +21.9% vs H1 FY26 H1 FY26 FY26 H1 FY26 FY26 H1 FY26 FY26 H1 FY26 FY26 19.5% 20.6% 18.1% 19.5% 1.4% 2.7% 1,628.4 1,7
Slide 12: Key Operating KPIs
Key Operating KPIs Bed Capacity ARPOB (Rs in ‘000) Occupied Bed Days & Occupancy % 2,211 2,211 48.4 48.9 +23.9% 200.7 1,502 1,502 162.1 559 559 59.0% 73.0% H1FY26 H1FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 Bed Capacity Operational Beds Occupancy ICU Beds IP Volumes (‘000) OP Consultations (‘000) ALOS (i
Slide 13: Specialty And Payor Mix
Specialty And Payor Mix Specialty Mix Payor Mix H1 FY’26: 75% Self-Pay + H1 FY’26: 69% H1 FY’27 : 56% CONGOR H1 FY’27: 74% Insurance Cardiac Self-Pay Sciences Oncology 20% 32% 13% H1 FY 26 23% 12% 43% H1 FY 27 H1 FY’26 13% Neuro 13% 24% Others Sciences 25% 31% 26% 8% 26% 8% 8% 11% Insurance Gastro S
Slide 14: 20 Years of Compassionate Care
20 Years of Compassionate Care CRISIL LEGACY BBB+ → A– 92% CRISIL upgraded the long- of employees say new term rating by one notch joiners are made to feel welcome Recognized UPGRADED CERTIFIED LISTED on 28 Oct 2026 Listed on NSE & BSE on 28 Oct 2026 · Times Now: #3 among multi-specialty groups of h
Slide 15: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (₹ Cr) Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY FY26 Revenue from Operations 510.9 416.1 +22.8% 981.2 784.5 +25.1% 1,606.0 Other Income 6.5 7.1 14.9 13.0 22.8 Total Income 517.3 423.2 +22.2% 996.1 797.5 +24.9% 1,628.8 COGS 123.3 114.2 238.4 216.4 430.2 Emp
Slide 16: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet Particulars (₹ Cr) Sep-26 Mar-26 Cash & Cash Equivalents(1) 305.9 302.7 Inventories 39.4 31.9 Trade Receivable 517.9 349.6 Property, Plant and Equipment & Capital Work-in-Progress 703.5 702.3 Right-of-Use Assets 521.4 531.1 Goodwill 4.6 4.6 Other Assets(2) 223.0 14
Slide 17: Pro Forma Debt Position post use of IPO Proceeds
Pro Forma Debt Position post use of IPO Proceeds Post-IPO Particulars (₹ Cr) As on 30th Sep 2026 Use of IPO Proceeds (Pro forma) Long-term borrowings 476.5 (375.0) 101.5 Short-term borrowings 502.5 – 502.5 Gross Debt 979.0 (375.0) 604.0 Cash & Cash Equivalents and bank 360.0 101.0* 461.0 deposits Ne
Slide 18: About Paras Healthcare
O32. +. PARAS T HEALTH About Paras Healthcare
Slide 19: High-Acuity Hospital Platform in North India: FY26
High-Acuity Hospital Platform in North India : FY26 8 2,211 ₹1,606 Cr Hospitals Beds Revenue from +2 upcoming · 5 to grow to ~3,011 by 2028 Operations States & 1 UT FY26 ₹47,398 2.9 days 75% ARPOB ALOS CONGOR share FY26 FY26 FY26 62% 1,011 ₹43.8 Cr Occupancy Doctors PAT 338,321 occupied bed Experien
Slide 20: Strong North & East India Footprint, Significant Opportunity for Growth
Strong North & East India Footprint, Significant Opportunity for Growth Strategic Presence across High-Demand Catchments North India healthcare Opportunity* Gurugram 1 Srinagar 2006 | Beds: 300 2023 | Beds: 200 CAGR 10–12% North Industry growth (FY26 to 30) Panchkula Kanpur 2018 | Beds: 284 2024 | B
Slide 21: From 200-bed hospital in 2006 to 3000+ beds by 2028
From 200-bed hospital in 2006 to 3000+ beds by 2028 First corporate hospitals 2017 · Investment 2025 · Investment INR 80 Cr primary in Gurugram (2006) and 360 ONE & Axis AIF INR 260 Cr primary Patna (2013)¹ Commelina (Creador affiliate) 2026 · Initial Public Offer Offer size – INR 1,450 Cr 500 beds
Slide 22: Leading Underserved Markets of North India Through an Asset-Light Model
Leading Underserved Markets of North India Through an Asset-Light Model 4 Mature Hospitals (>7 years) – 1,076 Beds Gurugram (Owned) Patna (Revenue share + partial fixed rent) Darbhanga (Revenue Share) Panchkula (Revenue share + partial fixed rent) Since 2006 Since 2013 Since 2016 Since 2018 First ho
Slide 23: Three Padma Shri awardees lead a clinical team backed by advanced technology
CLINICAL EXCELLENCE Three Padma Shri awardees lead a clinical team backed by advanced technology Dr. (Prof.) VS Dr. MV Padma Dr. (Prof.) Alka Dr. John Dr. Ahmad Mehta Srivastava Kriplani Mukhopadhyay Abdul Hai Chairman Emeritus - Chairperson – Chairperson – Director & Chief Consultant - Director – G
Slide 24: Doctor-led, professionally managed, independently governed
LEADERSHIP Doctor-led, professionally managed, independently governed Experienced Senior Management Team Dr. Kapil Garg Dilip Bidani Vineet Aggarwal Balkishan Sharma Dr. Sonia Verma Rahul Kumar Director, Strategy & Group CFO Group COO Group CHRO & Bus. Group Head, Projects Company Secretary & Growth
Slide 25: Listing on Indian Stock Exchanges – Beginning of a New Journey
Listing on Indian Stock Exchanges – Beginning of a New Journey Term Detail Offer size INR 1,450 Cr Fresh issue INR 500 Cr INR 950 Cr Offer for sale (Promoter INR 300 Cr; Commelina Ltd INR 650Cr) INR 375 Cr - Term debt Use of repayment proceeds: INR 125 Cr - General corporate purpose NSE and BSE – 28
Slide 26: What sets Paras Apart
What sets Paras Apart Strengths & Growth Strategies
Slide 27: The Paras Edge: Scale, Specialty, Efficiency, Excellence
The Paras Edge: Scale, Specialty, Efficiency, Excellence One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First-Mover Advantage Our first-mover advantage drives strong brand recognition in complex care services across key urban centres, including Gurugram, Patna, Pa
Slide 28: Robust IT Architecture Differentiates Our Service Delivery
Robust IT Architecture Differentiates Our Service Delivery Paras Health - IT Ecosystem Map Patient Engagement & Finance & Enterprise Digital Clinical Core Patient Digital Finance & Ops Communication Analytics & Operations Compliance iOS App Android CRM HIS EMR ERP Asset App Hospital Info Sys
Slide 29: Roadmap for Sustained, Profitable Growth
Roadmap for Sustained, Profitable Growth 1 2 3 4 5 Attract and Retain Improve Operational Expand North India High-End Clinical Scale Newer Hospitals Qualified and Efficiencies and Patient network programs Experienced Clinicians Experience • Ramp-up occupancy • Scale-up capacity in • Bone marrow, liv
Slide 30: Annexures
Annexures Paras Healthcare Limited (Private & Confidential)
Slide 31: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars H1FY27 FY26 FY25 Revenue from Operations 981.2 1,606.0 1,294.1 Consumption 238.4 430.2 336.8 Gross Profit 742.8 1,175.7 957.2 Gross Profit Margin 75.7% 73.2% 74.0% Employee Cost 113.9 181.6 173.8 Doctor Cost 232.8 394.1 358.9 Other Expenses
Slide 32: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet ASSETS Sept-26 Mar-26 Mar-25 EQUITY AND LIABILITIES Sept-26 Mar-26 Mar-25 Non-current assets Equity Property, plant and equipment 651.4 673.5 645.6 Equity Share capital 10.1 10.1 9.8 Capital work-in-progress 52.2 28.7 37.8 Other equity 476.0 384.8 270.7 Other in
Slide 33: Thank You!
Thank You ! Paras Healthcare Limited Strategic Growth Advisors Private Limited (SGA) CIN: U85110HR1987PLC035823 CIN: U74140MH2010PTC204285 Mr. Dilip Bidani / Mr. Sidharth Aggarwal Mr. Sagar Shroff / Mr. Ayush Haria Email ID : Dilip.Bidani@parashealth.com sagar.shroff@sgapl.net / ayush.haria@sgapl.ne
Paras Healthcare — Q2 & H1 FY27 Earnings Presentation on 6ix